Tag Archive for: pamrevlumab

Following a handful of clinical failures and changes to its leadership, FibroGen is trying to chart a more positive path forward by focusing on four strategic areas.

Following several clinical failures for its candidates Roxadustat and pamrevlumab, FibroGen CEO Enrique Conterno is stepping down for “personal reasons,” the company announced Tuesday.

The company was evaluating the efficacy and safety of pamrevlumab in a late-stage trial in patients with non-ambulatory Duchenne muscular dystrophy (DMD), where upper limb function of the patients are affected, versus a placebo.